This Study Will Investigate the Effectiveness of Peppermint Oil Inhalation in Reducing the Intensity and Frequency of Acute Nausea and Vomiting Among Cancer Patients Undergoing Chemotherapy. Chemotherapy-induced Nausea and Vomiting (CINV) Are Among the Most Distressing Side Effects Experienced by pa

Launched by UNIVERSITY OF HEALTH SCIENCES LAHORE · Apr 22, 2025

Keywords

ClinConnect Summary

This clinical trial is exploring whether inhaling peppermint oil can help reduce nausea and vomiting in cancer patients who are undergoing chemotherapy. These symptoms are common and can be very distressing, even leading to dehydration and weight loss. While there are medications available to help with nausea, they can have unpleasant side effects and may be costly. This study aims to see if peppermint oil, a natural remedy, can provide an effective and safer alternative.

To participate, you must be between 20 and 50 years old, undergoing chemotherapy at Jinnah Hospital in Lahore, and able to understand Urdu or Punjabi. You will be placed in one of two groups: one will inhale peppermint oil, while the other will inhale a non-active substance (placebo). The trial will gather information on how well peppermint oil works compared to the placebo. If successful, this could be a simple and low-cost way to help manage nausea and vomiting for many patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • • Participants undergoing chemotherapy in the outpatient oncology department of Jinnah Hospital Lahore.
• • Participants ages 20-50 years.
• • Participants of Both genders' male and female.
• • Participants who have undergone under one cycle of chemotherapy.
• • Participants who can understand and comprehend Urdu and Punjabi language
• Exclusion Criteria:
• • Participants who are allergic to peppermint products.
• • Participants who have any psychiatric illness.
• • Participants diagnosed with any respiratory illness.
• • Participants who have vomiting due to any ailment other than chemotherapy.
• • Participants with Gastro-intestinal and Hepatobiliary Tumors.